Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -6.20% | 0.87% | -4.34% | -1.97% | 15.98% |
| Total Other Revenue | -- | -- | -103.87% | -104.06% | 18.36% |
| Total Revenue | -6.20% | 0.87% | -5.14% | -2.72% | -6.94% |
| Cost of Revenue | 8.30% | 40.49% | 16.18% | -5.53% | -13.51% |
| Gross Profit | -10.39% | -8.25% | -18.83% | 0.28% | -4.85% |
| SG&A Expenses | -4.72% | 33.62% | -6.30% | -4.71% | -20.15% |
| Depreciation & Amortization | 38.27% | 7.79% | -21.63% | -24.96% | -18.65% |
| Other Operating Expenses | 54.26% | 11.48% | 93.54% | 148.68% | 152.30% |
| Total Operating Expenses | 1.39% | 34.21% | 8.36% | 2.94% | -11.90% |
| Operating Income | -28.52% | -67.20% | -30.18% | -19.39% | 11.53% |
| Income Before Tax | -51.71% | -110.30% | -44.48% | 27.38% | 42.84% |
| Income Tax Expenses | -21.36% | -130.86% | -47.02% | -59.63% | -87.75% |
| Earnings from Continuing Operations | -54.70% | -106.02% | -43.96% | 77.39% | 2,780.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -11.11% | 200.00% | -142.86% | -99.65% | -99.77% |
| Net Income | -54.63% | -106.00% | -44.08% | 27.68% | 49.48% |
| EBIT | -28.52% | -67.20% | -30.18% | -19.39% | 11.53% |
| EBITDA | -21.40% | -58.17% | -27.94% | -19.78% | 7.26% |
| EPS Basic | -54.88% | -105.98% | -43.62% | 30.07% | 52.39% |
| Normalized Basic EPS | -40.25% | -63.10% | -19.85% | -23.73% | -41.91% |
| EPS Diluted | -54.89% | -106.00% | -43.78% | 29.61% | 52.01% |
| Normalized Diluted EPS | -40.13% | -62.99% | -20.13% | -23.89% | -42.11% |
| Average Basic Shares Outstanding | 0.56% | 0.28% | -0.82% | -1.84% | -1.91% |
| Average Diluted Shares Outstanding | 0.34% | 0.00% | -0.48% | -1.63% | -1.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |